Compositions comprising reproductive cell media and methods for using such compositions

• US 6,849,394 B2
• Filed: 02/21/2002
• Issued: 02/01/2005
• Est. Priority Date: 02/21/2002
• Status: Expired due to Fees

• Current Assignee: Mofa Group, Llc
• Original Assignee: Minitube of America Incorporated (Minitub GmbH)
• Inventors: Rozeboom, Kevin J., Wilson, Mark E.
• Primary Examiner(s): Afremova, Vera
• Application Number:
  US10/081,097
• Publication Number:
  US 20030157473A1
• Time in Patent Office: 1,076 Days
• Field of Search: 435/2, 435/404
• US Class Current: 435/2
• CPC Class Codes: A01N 1/021 Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
• CPC Class Codes: A61K 35/52 Sperm; Prostate; Seminal fluid; Leydig cells of testes
• CPC Class Codes: C12N 5/061 Sperm cells, spermatogonia

Abstract

Disclosed are compositions for mammalian, avian or piscian reproductive cells and methods for the collection, holding, processing, in vitro fertilization, sexing culturing, or storing (including long-term cryopreservation) of mammalian, avian, or piscian reproductive sperm cells. The compositions comprise a suitable reproductive cell media and a transforming growth factor, an insulin-like growth factor, or zinc, and, optionally, inositol, transferrin, or fructose, or combinations thereof.

Claims

1. A composition comprising a sperm cell and a medium, wherein the medium comprises at least one insulin-like growth factor and at least one transforming growth factor, and wherein the medium is a collection, holding, processing, in vitro fertilization, sexing, culturing or storage medium.

2. The composition of claim 1, wherein the sperm cell is a mammalian sperm cell.

3. The composition of claim 2, wherein the sperm cell is a porcine sperm cell.

4. The composition of claim 2, wherein the sperm cell is an equine sperm cell.

5. The composition of claim 2, wherein the sperm cell is a bovine sperm cell.

6. The composition of claim 2, wherein the sperm cell is an ovine sperm cell.

7. The composition of claim 2, wherein the sperm cell is a human sperm cell.

8. The composition of claim 1, wherein the sperm cell is an avian sperm cell.

9. The composition of claim 1, wherein the sperm cell is a piscian sperm cell.

10. The composition of claim 1, wherein the transforming growth factor comprises TGFβ

-1.

11. The composition of claim 1, wherein the transforming growth factor comprises TGFβ

-2.

12. The composition of claim 1, wherein the transforming growth factor comprises TGFβ

-1 and TGFβ

-2.

13. The composition of claim 1, wherein the insulin-like growth factor comprises IGFβ

-1.

14. The composition of claim 12, wherein the medium further comprises IGFβ

-1.

15. The composition of claim 1, wherein the medium further comprises at least one component selected from the group consisting of inositol, transferrin, and fructose.

16. The composition of claim 10, wherein the medium is in liquid form and the TGFβ

-1 is present in a concentration from about 0.1 ng/L to about 10 μ

L.

17. The composition of claim 16, wherein the TGFβ

-1 is present in a concentration from about 20 ng/L to about 400 ng/L.

18. The composition of claim 17, wherein the TGFβ

-1 is present in a concentration from about 50 ng/L to about 150 ng/L.

19. The composition of claim 11, wherein the medium is in liquid form and the TGFβ

-2 is present in a concentration from about 0.1 ng/L to about 200 ng/L.

20. The composition of claim 19, wherein the TGFβ

-2 is present in a concentration from about 0.4 ng/L to about 16 ng/L.

21. The composition of claim 19 wherein the TGFβ

-2 is present in a concentration from about 1.8 ng/L to about 3.8 ng/L.

22. The composition of claim 13, wherein the medium is in liquid form and the IGF-1 is present in a concentration from about 0.1 ng/L to about 30 μ

g/L.

23. The composition of claim 22 wherein the IGF-1 is present in a concentration from about 40 ng/L to about 640 ng/L.

24. The composition of claim 22, wherein the IGF-1 is present in a concentration from about 200 ng/L to about 450 ng/L.

25. The composition of claim 1, wherein the medium further comprises a cryopreservative.

26. The composition of claim 1, wherein the medium further comprises zinc.

27. The composition of claim 3, wherein the medium comprises TGFβ

-1, TGFβ

-2, and IGF-1.